Many plants have the property of wound healing, but most of the people are using costly allopathic medicine for the wound. This might be due to lack of awareness about the traditional uses and lack of scientific study of ethnomedicinal plants. So, this study aimed to carry out the antibacterial and antioxidant activity of two medicinal plants which are used traditionally for wound healing activity, i.e.,Mimosa rubicaulis and Reinwardtia indica. Different parts of Mimosa rubicaulis (root, stem, and leaves) and Reinwardtia indica (flower and leaves) were used for the study. Extractions were done by maceration using ethanol as solvent. Antibacterial activity was carried out by the well diffusion method, and antioxidant activities were screened by DPPH radical scavenging and NO scavenging assays. Extract of M. rubicaulis has shown a weak zone of inhibition towards S. aureus and P. vulgaris whereas R. indica has shown no zone of inhibition towards selected bacterial strains. Leaf, root, and stem extracts of M. rubicaulis have shown potent antioxidant activity, i.e., IC50 value of 9.8 µg/ml, 10.19 µg/ml, and, 13.64 µg/ml, respectively. Similarly, leaf extract of R. indica exhibited antioxidant activity with an IC50 value of 19.73 μg/ml. The percentage inhibition of NO radicals of root and stem of M. rubicaulis and leaves of R. indica was 31%, 21%, and 22%, respectively. Out of these two plant species, M. rubicaulis had shown antibacterial activity towards selected microorganism, but antioxidant activity was shown by both plant species. These properties on above mentioned two plant species might help for the development of a marketed formulation for antibacterial and wound-healing agent since wound healing is promoted by antibacterial and antioxidant activities.

Antiviral and antibacterial properties of phloroglucinols: a review on naturally occurring and (semi)synthetic derivatives with potential therapeutic interest

Background: Pain and inflammation are major health problems. The adverse effect of synthetic drugs for the management of painful inflammatory conditions gives a strong motivation for researchers to develop newer drugs with a lesser side effect. Mimosa rubicaulis has been used traditionally in rheumatism, fungal infection, wound, fever, etc. Objective: The objective was to evaluate the anti-inflammatory and analgesic activity of ethanolic stem extract of M. rubicaulis in Swiss albino rats. Methods: The stem of M. rubicaulis were collected, subjected to double maceration using ethanol as a solvent. Then, swiss albino rats (n=72) were taken. An acute toxicity study was conducted using different doses of plant extract. The antiinflammatory activity (100 mg/kg, 250 mg/kg) was evaluated using the carrageenan-induced paw edema test. While, analgesic activity (100 mg/kg, 250 mg/kg) was evaluated using a hot plate and tail immersion method. The result was analyzed using a one-way Analysis of variance and post hoc analysis with the Tukey test. Results: The acute toxicity study showed that the plant is safe for use in an animal model. The extract showed antiinflammatory activity by a reduction in paw edema volume i.e. 25%, and 48%. Similarly, analgesic activity was shown by an increase in latency of paw licking and tail withdrawal by 41%, 56% (hot plate method) and 39%, and 54% (Tail immersion method), p<0.05. Conclusion: It can be concluded that ethanolic extract of Mimosa rubicaulis is safe and possesses both anti-inflammatory and analgesic activity.

Introduction: Patients with COVID-19 are characterised by abnormal levels of inflammatory biomarkers. Elevated D-dimer in COVID-19 patients is associated with increased mortality. This study aimed to find out the prevalence of raised D-dimer among COVID-19 patients in a tertiary care centre. Methods: This descriptive cross-sectional study was conducted in COVID-19 unit of a tertiary care centre from 23 January 2021 to 19 June 2021. The ethical approval was taken from the Institutional Review Committee (Reference number: 077/078/159). D-dimer values and demographic data of the hospital-admitted COVID-19 patients were recorded. Convenience sampling technique was used. Point estimate and 95% Confidence Interval were calculated. Results: Out of 180 patients with COVID-19 admitted in the hospital, the D-dimer levels were raised in 85 (47.22%) (39.93-54.51, 95% Confidence Interval) patients. Conclusions: The prevalence of raised D-dimer among admitted COVID-19 patients was found to be lower when compared to other studies conducted in similar settings.